Clinical Trial Update: Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders [Phase 4]

View source ↗

Summary

Phase 4 open-label trial evaluating N-Acetylcysteine in children and adolescents (5-17) with bipolar spectrum disorders has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Bipolar Disorder | Phase 4 | Status: COMPLETED | Results posted: 2019-11-04